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Introduction
Cancer of the anus is a rare disease whose incidence is steadily rising [1] . Around 1,000 cases are now diagnosed in the UK each year with the majority of cases squamous cell carcinoma (SCC). In 1980, radical surgery was the standard treatment for SCC of the anus. Single centres then started to report high rates of durable complete response to radiotherapy alone or with the combination of chemotherapy and radiotherapy, with surgery reserved as a salvage therapy [2, 3] .
In the UK, the United Kingdom Coordinating Centre for Cancer Research (UKCCCR) anal working party designed the first (ACT1) anal cancer trial [4] . Rather than compare radical surgery against nonsurgical treatment, a two-arm trial was designed that compared radiotherapy alone versus concurrent chemotherapy using Mitomycin C (MMC) and 5Fluorourcil (5FU). In both arms, a fiveweek course of radiotherapy was used with a subsequent radiotherapy boost in responding patients.
Early salvage surgery was recommended for patients not responding to the initial course of treatment. The trial randomised 577 patients between 1987 and 1994.
At the same time the European Organisation for Research and Treatment of Cancer (EORTC) trial used the same design and recruited 110 patients [5] . In the USA, the Radiation Therapy Oncology Group (RTOG) trial compared 5FU and radiotherapy with MMC 5FU and radiotherapy in 310 patients [6] . The consistent finding across the three trials was that MMC 5FU and radiotherapy led to the highest rate of locoregional control, thus reducing the need for radical surgery and colostomy.
In this study we explore the impact of the ACT1 trial on routine population based clinical practice.
We hypothesise that surgery was the standard of care prior to the trial and that the outcome of the ACT1 along with the other two international trials would lead to a change in routine clinical practice after the results of the trial were presented/published.
Data & methods
All patients diagnosed with a first primary cancer of the anus and/or anal canal (International Classification of Diseases Version 10 code C21 [7] ) in England between 1981 and 2010 were identified from the cancer registry component of the National Cancer Data Repository (NCDR). Cases were limited to those with squamous cell, basaloid and cloacogenic cancers based on their ICD-O morphology codes [8] .
Robust treatment information is not available from all of the cancer registries that contribute data to the NCDR. In order to look at treatment patterns over time, cases of anal cancer (criteria as above) The proportion of patients within each treatment group was calculated for each calendar year and in seven-year cohorts corresponding to the periods prior to, during and after the ACT1 trial. Threeyear relative survival (which takes into account the background mortality of the population) in the Yorkshire and national cohorts was calculated for the same seven-year periods command in STATA version 13.1 (for cases diagnosed up to 2008 to allow sufficient follow-up time).
Results
Between 1981 and 2010, 11,743 individuals were diagnosed with SCC of the anal canal in England.
During the same period in the Yorkshire region, 1,065 cases of anal cancer were diagnosed. Table 1 and Figure 1 show the changes in treatment for anal cancer over the study period. This dramatic change in management of a rare disease from surgery to non-surgical treatment is relatively unusual in solid tumour oncology. These findings emphasise a key benefit of a phase III trial. The rapid uptake of chemoradiotherapy was also likely related to the strong advocacy by leading surgeons with experience of both surgical and chemoradiotherapy outcomes. In this example the observed treatments used and the results not only apply to the selected clinical trial population but were extended to change population-based practice.
Treatment in the Yorkshire region
We also demonstrate that population-based survival improved in England throughout the study period, with the most significant increase occurring from 1996. We cannot determine a direct causal relationship as other factors, such as the increasing prevalence of Human Papilloma Virus driven malignancy may be relevant. However, it is likely that the change from surgery to chemoradiotherapy contributed to the observed improvement in survival rates. CRT additionally treated all pelvic and inguinal nodes in addition to the primary tumour. The absolute improvement in relative survival throughout the study period is approximately 25% for both the English and
Yorkshire data
Few studies have investigated the impact of different treatment regimens on patient outcomes at a population-level. In the US, a study of 38,882 patients with anal cancer found that those undergoing recommended treatment (primary chemoradiotherapy with or without surgery) had an 18% lower risk of death within five years than those who underwent non-guideline treatment [14] . Large singlecentre series have shown similar results. For example, a study of 308 patients in the Stockholm region of Sweden found that patients treated with neoadjuvant platinum-based chemotherapy had significantly better complete response rates and increased overall five-year survival than patients treated with radiotherapy with or without bleomycin [15] . In the UK, a series of 254 treated at a regional cancer centre demonstrated that chemoradiotherapy was associated with a significant improvement in local control in comparison to radiotherapy alone and this effect persisted six years after initial treatment [16] .
The main limitation to this study is the lack of robust treatment data for the whole country. Whilst data quality has improved in recent years with the introduction of the National Cancer Intelligence
Network and other initiatives, historically it has varied from region to region, with some collecting virtually no treatment information. The data from Yorkshire represent around 10% of the patient population, with two radiotherapy centres and nine referring NHS Trusts. There is no reason to suggest that treatment or referral patterns in Yorkshire would differ from other regions in England.
Linkage to other datasets, such as Hospital Episode Statistics, can overcome some of the limitations of cancer registration data but, again, historically coding was not as reliable as it is for recent years.
Conclusion
Population-based treatment for SCC anus changed dramatically during the study period. The predominant use of surgery prior to ACT1, a transition phase during the trial and a dramatic increase in the use of CRT after ACT1 provides strong evidence of the impact of the ACT1 trial on populationbased practice. A significant improvement in survival was also observed.
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